Organon introduces global ESG strategy
Report lays out blueprint for achieving Organon’s purpose and business imperatives to help women and girls achieve their promise through better health
Report lays out blueprint for achieving Organon’s purpose and business imperatives to help women and girls achieve their promise through better health
Dr Rupali Paranjape, an experienced regulatory and compliance consultant and author of Blue Ocean of Compliance shares insights on her book in an interview with Thomas C Thottathil, Editor, www.indianpharmapost.com
Dupixent peak sales ambition raised to more than €13 billion
Ritika has also extensively worked with clients such as WHO, GAVI Alliance, USAID, Gilead, Novartis, Sanofi Pasteur
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Bayer expects 2025 to be the most difficult year of its turnaround
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
Subscribe To Our Newsletter & Stay Updated